Expanding the Market and Success Rates for Myeloablative Cancer Treatments Using PUL-042, an Innate Immune Stimulant
$982,488R44FY2015HLNIH
Pulmotect, Inc, Houston TX
Investigators
Abstract
? DESCRIPTION (provided by applicant):
View original record on NIH RePORTER →